U.S. Pharmacogenetic Testing Market to 2032
Overview
The U.S. Pharmacogenetic Testing Market is expected to reach a 3.16 USD Billion by 2032 and is projected to grow at a CAGR of 14.84% from 2025 to 2032.
Revenue, 2024 (USD Billion)
1.43
Forecast, 2032 (USD Billion)
3.16
CAGR, 2024 - 2032
14.84%
Report Coverage
U.S.
U.S. Pharmacogenetic Testing Market 2018-2032 USD Billion
U.S. Pharmacogenetic Testing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 1.43 USD Billion
- Projected Market Size (2032): 3.16 USD Billion
- CAGR (2025-2032): 14.84%
Key Findings of U.S. Pharmacogenetic Testing Market
- The U.S. Pharmacogenetic Testing Market was valued at 1.43 USD Billion in 2024.
- The U.S. Pharmacogenetic Testing Market is likely to grow at a CAGR of 14.84% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Blood in Sample Segment accounted for the largest share of the market with a revenue of 0.76 USD Billion
- The fastest growing segment Cardiology in Therapeutic Area Segment grew Fastest with a CAGR of 18.60% during the forecast period from 2024 to 2032.
U.S. Pharmacogenetic Testing Market Scope
U.S. Pharmacogenetic Testing Market Segmentation & Scope
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Sample
- Saliva
- Blood
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
U.S. Pharmacogenetic Testing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 1.43 USD Billion |
| Market Value in 2032 | 3.16 USD Billion |
| CAGR (2025-2032) | 14.84% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Distribution Channel,End User,Application,Therapeutic Area,Sample,Drug,Gene,Type |
Regional Insights:
-
Leading Market (2024-2032): U.S., leading in terms of revenue 1.43 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 1,430.72 USD Million in 2024.
Segments and Scope
-
U.S. Pharmacogenetic Testing Market to 2032, By Distribution Channel
- Hospital Pharmacy is the largest segment in U.S. Pharmacogenetic Testing Market to 2032 with a revenue of 647.21 USD Billion in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in U.S. Pharmacogenetic Testing Market to 2032 with a Growth rate of 15.54 % in forecast period 2025-2032.
-
U.S. Pharmacogenetic Testing Market to 2032, By End User
- Healthcare Providers is the largest segment in U.S. Pharmacogenetic Testing Market to 2032 with a revenue of 573.96 USD Billion in the year 2024.
- Healthcare Providers is the Fastest growing segment in U.S. Pharmacogenetic Testing Market to 2032 with a Growth rate of 15.65 % in forecast period 2025-2032.
-
U.S. Pharmacogenetic Testing Market to 2032, By Application
- Clinical Practice is the largest segment in U.S. Pharmacogenetic Testing Market to 2032 with a revenue of 636.11 USD Billion in the year 2024.
- Clinical Practice is the Fastest growing segment in U.S. Pharmacogenetic Testing Market to 2032 with a Growth rate of 15.63 % in forecast period 2025-2032.
-
U.S. Pharmacogenetic Testing Market to 2032, By Therapeutic Area
- Cardiology is the largest segment in U.S. Pharmacogenetic Testing Market to 2032 with a revenue of 327.68 USD Billion in the year 2024.
- Cardiology is the Fastest growing segment in U.S. Pharmacogenetic Testing Market to 2032 with a Growth rate of 18.60 % in forecast period 2025-2032.
-
U.S. Pharmacogenetic Testing Market to 2032, By Sample
- Blood is the largest segment in U.S. Pharmacogenetic Testing Market to 2032 with a revenue of 762.68 USD Billion in the year 2024.
- Blood is the Fastest growing segment in U.S. Pharmacogenetic Testing Market to 2032 with a Growth rate of 15.05 % in forecast period 2025-2032.
-
U.S. Pharmacogenetic Testing Market to 2032, By Drug
- Prescription Drugs is the largest segment in U.S. Pharmacogenetic Testing Market to 2032 with a revenue of 467.01 USD Billion in the year 2024.
- Prescription Drugs is the Fastest growing segment in U.S. Pharmacogenetic Testing Market to 2032 with a Growth rate of 16.79 % in forecast period 2025-2032.
-
U.S. Pharmacogenetic Testing Market to 2032, By Gene
- CYP2C19 is the largest segment in U.S. Pharmacogenetic Testing Market to 2032 with a revenue of 311.17 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in U.S. Pharmacogenetic Testing Market to 2032 with a Growth rate of 18.20 % in forecast period 2025-2032.
-
U.S. Pharmacogenetic Testing Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in U.S. Pharmacogenetic Testing Market to 2032 with a revenue of 672.22 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in U.S. Pharmacogenetic Testing Market to 2032 with a Growth rate of 15.49 % in forecast period 2025-2032.
U.S. Pharmacogenetic Testing Market Company Share Analysis
| Company Name |
|
||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| QIAGEN | |||
| Sonic Healthcare Limited | |||
| BGI | |||
U.S. Pharmacogenetic Testing Market Geographical Sales Distribution, 2018-2032 USD Billion
U.S. Pharmacogenetic Testing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The U.S. Pharmacogenetic Testing Market is segmented based on Segmentation Distribution Channel,End User,Application,Therapeutic Area,Sample,Drug,Gene,Type.
U.S. Pharmacogenetic Testing Market was valued at USD 1.43(Revenue in USD Billion) in 2021.
U.S. Pharmacogenetic Testing Market is projected to grow at a CAGR of 14.84% during the forecast period of 2024 to 2032.
The Blood segment is expected to dominate the U.S. Pharmacogenetic Testing Market, holding a largest market share of 0.76 USD Billion in 2024
U.S. Pharmacogenetic Testing Market Scope
U.S. Pharmacogenetic Testing Market Segmentation & Scope
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Sample
- Saliva
- Blood
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
Frequently Asked Questions
The U.S. Pharmacogenetic Testing Market is segmented based on Segmentation Distribution Channel,End User,Application,Therapeutic Area,Sample,Drug,Gene,Type.
U.S. Pharmacogenetic Testing Market was valued at USD 1.43(Revenue in USD Billion) in 2021.
U.S. Pharmacogenetic Testing Market is projected to grow at a CAGR of 14.84% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Pharmacogenetic Testing Market for final year is USD 3.16 (USD Billion).
U.S. Pharmacogenetic Testing Market Company Profiling
Frequently Asked Questions
The U.S. Pharmacogenetic Testing Market is segmented based on Segmentation Distribution Channel,End User,Application,Therapeutic Area,Sample,Drug,Gene,Type.
U.S. Pharmacogenetic Testing Market was valued at USD 1.43(Revenue in USD Billion) in 2021.
U.S. Pharmacogenetic Testing Market is projected to grow at a CAGR of 14.84% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Pharmacogenetic Testing Market for final year is USD 3.16 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.